Ignite Creation Date:
2024-05-06 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05142228
Status:
TERMINATED
Last Update Posted:
2024-03-22
First Post:
2021-10-29
Brief Title:
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain TNP
Status:
TERMINATED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low enrollment rate
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single center placebo-controlled double blind randomized phase II pilot to evaluate the efficacy of erenumab-aooe in the management of trigeminal neuropathic pain comparing erenumab-aooe vs Placebo
A total of 40 patients 20 each arm aged 18-65 years old of either sex and any race or ethnicity presenting trigeminal neuropathic pain will be randomly assigned in a 11 parallel double-blind clinical trial to receive either Erenumab or placebo Participants will attend 6 clinic visits Visit 0-Visit 5 over a period of 21 weeks Changes in pain intensity and other pain related outcomes of trigeminal neuropathic pain will be assessed Blood samples will be collected and participants will need to keep a daily symptom diary and answer some other questionnaires
A total of 40 patients 20 each arm aged 18-65 years old of either sex and any race or ethnicity presenting trigeminal neuropathic pain will be randomly assigned in a 11 parallel double-blind clinical trial to receive either Erenumab or placebo Participants will attend 6 clinic visits Visit 0-Visit 5 over a period of 21 weeks Changes in pain intensity and other pain related outcomes of trigeminal neuropathic pain will be assessed Blood samples will be collected and participants will need to keep a daily symptom diary and answer some other questionnaires
Detailed Description:
TNP are a considerable burden and affects significantly the quality of life of the sufferer There are medications for their management but while they may work for some patients may not work for the others in addition side effects may be present for some patients with the need to decrease dosage to not optimal levels Furthermore the indications of these drugs are for other neuropathic pain disorders and currently there is no medication specifically indicated for the management of TNP based on its molecular pathophysiology
The calcitonin gene-related peptide CGRP is a key neuropeptide involved in migraine pathophysiology There is evidence showing that CGRP has a role in other disorders mediated by the trigeminal system in addition to migraine CGRP has shown to have a role in orofacial pain such as in TMD and in trigeminal neuropathic pain Erenumab-aooe is the first antibody therapeutic targeting the CGRP receptor with FDA approval for migraine prevention that is well tolerated and with a good safety profile Therefore the scientific premise for this study is that inhibiting the CGRP pathway in trigeminal neuropathic pain will decrease pain and pain related outcomes in a safe and well tolerated manner for this patient population
Potential participants will be pre-screened at the Brotman Facial Pain clinic at the Oral and Maxillofacial Surgery Clinic both at the University of Maryland School of Dentistry at the Pain Medicine Clinic at the University of Maryland School of Medicine or by telephone those willing to participate will be scheduled for a screening and baseline visit Visit 0 During this visit potential participants will be evaluated for eligibility for trigeminal neuropathic pain subjects with diagnosis based on the International classification of headache disorders ICHD-3 and International classification of Orofacial Pains ICOP of idiopathic trigeminal neuralgia with concomitant continuous pain painful posttraumatic trigeminal neuropathy or idiopathic painful trigeminal neuropathy and written informed consent will be obtained The screening and baseline procedures include medical history review clinical examinations tests and administration of questionnaires Instructions will be given for the completion of a Daily Symptom Diary DSD and other questionnaires at home or online Participants who show compliance with 80 completion of the DSD and who meet the pain score inclusion criteria for 4 weeks28 days during the baseline period from Visit 0 will be randomly assigned to one of two groups either the investigational drug or placebo and will be scheduled for Visit 1
The study drug is Erenumab 140 mg SC injection Participants will attend 6 clinic visits Visit 0-Visit 5 After randomization and on Visit 1 the participant will receive the drug or placebo This same treatment will be administered once a month for 3 months 3 cycles12weeks
The calcitonin gene-related peptide CGRP is a key neuropeptide involved in migraine pathophysiology There is evidence showing that CGRP has a role in other disorders mediated by the trigeminal system in addition to migraine CGRP has shown to have a role in orofacial pain such as in TMD and in trigeminal neuropathic pain Erenumab-aooe is the first antibody therapeutic targeting the CGRP receptor with FDA approval for migraine prevention that is well tolerated and with a good safety profile Therefore the scientific premise for this study is that inhibiting the CGRP pathway in trigeminal neuropathic pain will decrease pain and pain related outcomes in a safe and well tolerated manner for this patient population
Potential participants will be pre-screened at the Brotman Facial Pain clinic at the Oral and Maxillofacial Surgery Clinic both at the University of Maryland School of Dentistry at the Pain Medicine Clinic at the University of Maryland School of Medicine or by telephone those willing to participate will be scheduled for a screening and baseline visit Visit 0 During this visit potential participants will be evaluated for eligibility for trigeminal neuropathic pain subjects with diagnosis based on the International classification of headache disorders ICHD-3 and International classification of Orofacial Pains ICOP of idiopathic trigeminal neuralgia with concomitant continuous pain painful posttraumatic trigeminal neuropathy or idiopathic painful trigeminal neuropathy and written informed consent will be obtained The screening and baseline procedures include medical history review clinical examinations tests and administration of questionnaires Instructions will be given for the completion of a Daily Symptom Diary DSD and other questionnaires at home or online Participants who show compliance with 80 completion of the DSD and who meet the pain score inclusion criteria for 4 weeks28 days during the baseline period from Visit 0 will be randomly assigned to one of two groups either the investigational drug or placebo and will be scheduled for Visit 1
The study drug is Erenumab 140 mg SC injection Participants will attend 6 clinic visits Visit 0-Visit 5 After randomization and on Visit 1 the participant will receive the drug or placebo This same treatment will be administered once a month for 3 months 3 cycles12weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None